z-logo
open-access-imgOpen Access
Platelet‐to‐lymphocyte ratio predicts the prognosis of patients with non‐small cell lung cancer treated with surgery and postoperative adjuvant chemotherapy
Author(s) -
Toda Michihito,
Tsukioka Takuma,
Izumi Nobuhiro,
Komatsu Hiroaki,
Okada Satoshi,
Hara Kantaro,
Miyamoto Hikaru,
Ito Ryuichi,
Shibata Toshihiko,
Nishiyama Noritoshi
Publication year - 2018
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12547
Subject(s) - medicine , chemotherapy , proportional hazards model , hazard ratio , adjuvant , lung cancer , oncology , adjuvant therapy , cancer , gastroenterology , surgery , confidence interval
Background Markers of preoperative tumor immunity, such as platelet‐to‐lymphocyte ratio (PLR), have been reported to be prognostic factors for patients with various cancers. However, the relationship between PLR and the prognosis of non‐small cell lung cancer (NSCLC) patients treated with surgery and adjuvant chemotherapy as a multidisciplinary treatment is unknown. Methods We enrolled 327 NSCLC patients treated surgically with or without adjuvant chemotherapy (78 and 249 patients, respectively) at our hospital from 2008 to 2012. Patients had no preoperative hematological disease or infection. Preoperative PLR and clinicopathologic characteristics were recorded and their potential associations and prognostic values were assessed by Kaplan–Meier and multivariate Cox regression. The optimal cut‐off value for high and low PLR was calculated from receiver operating characteristic curves. Results The five‐year overall survival rates for patients with low and high PLR were 78% and 57% ( P  < 0.01) for all patients, and 69% and 37% ( P  < 0.01) for patients who received adjuvant chemotherapy, respectively. Similarly, the five‐year disease‐free survival rates for patients with low and high PLR were 66% and 62% ( P  = 0.03) for all patients, and 47% and 14% ( P  < 0.01) for patients who received adjuvant chemotherapy, respectively. Cox proportional hazard regression indicated that high PLR was an independent prognostic factor for both overall and disease‐free survival in the adjuvant chemotherapy group. Conclusion Elevated PLR predicts poor prognosis in surgically treated NSCLC patients, especially those who receive adjuvant chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here